A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
Phase 2
120
about 7.1 years
18+
2 sites in MI, PA
About this study
Researchers are testing the safety and effectiveness of a treatment called Afimkibart (also known as RO7790121) for people with atopic dermatitis who have already taken part in other afimkibart clinical trials. The trial will last 2591 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Afimkibart
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Percentage of Participants with Adverse Events
Secondary: Change From Baseline (in Parent Study) in Eczema Area and Severity Index (EASI) Score at Each Visit, Change from Baseline (in the parent study) in Dermatology Life Quality Index (DLQI) at Each Visit, Change from Baseline (in the parent study) in Participant-Oriented Eczema Measure (POEM) at Each Visit, Percent Change From Baseline (in Parent Study) in EASI Score at Each Visit
Dermatology